ArticleFrontiers in cardiovascular medicine2025
Pregnancy hormones increase cardiac capillary density via the PGC-1α/ERRα/VEGF pathway in cardiomyocytes.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pregnancy significantly affects the maternal cardiovascular system, with physiological adaptations characterized by cardiac hypertrophy and increased capillarization. However, the molecular mechanisms underlying these adaptations remain incompletely understood. Therefore, we analyzed them in mouse hearts at different stages of pregnancy and after hormone treatment. Methods: We analyzed cell proliferation, capillary density, hypertrophy, and gene expression using immunostaining and quantitative RT-PCR to evaluate differential gene expression in mouse hearts at different stages during pregnancy and after treatment with combinations of progesterone and estrogen for up to 14 days. Results: We found that the number of proliferating cells in the hearts of pregnant mice began to increase at gestational day 3 (GD3), peaked at GD14-mainly in fibroblasts and endothelial cells (ECs), but not in cardiomyocytes (CMs)-and decreased immediately after delivery. EC proliferation was indicative of angiogenesis, as evidenced by increased capillary density. After hormone treatment, capillary density increased in the hearts of both female and male mice, without prominent CM hypertrophy and independently of nuclear hormone receptors. The proportion of proliferating cardiac cells and ECs was significantly increased after 14 days of treatment. Mechanistically, we identified activation of the PGC-1α/ERRα signaling pathway and upregulation of its downstream target VEGF-A. Using a CM-specific PGC-1α knockout mouse line, we demonstrated that the pregnancy hormone-induced angiogenesis is induced via PGC-1α signaling in CMs by secretion of VEGF. Conclusions: Our data indicated a direct effect of pregnancy hormones on cardiac capillarization, rather than indirect effects through CM hypertrophy, and demonstrate that capillary expansion is not sufficient to drive physiological hypertrophy. Pregnancy hormones directly act on CMs via the PGC-1α/ERRα signaling pathway and VEGF secretion, positioning CMs as a key source of angiogenic factors that promote endothelial cell proliferation and enhance capillary density in the heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.